ArticlePloS one2026

Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells.

Kitiya Rujimongkon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.